Sleisenger and Fordtran’s Gastrointestinal and Liver Disease
暂无分享,去创建一个
[1] Y. Maehara,et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. , 2006, Gastroenterology.
[2] D. Steensma,et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained , 2006, Leukemia.
[3] R. Lai,et al. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. , 2006, Blood.
[4] P. Campbell,et al. Mechanisms of Disease The Myeloproliferative Disorders , 2006 .
[5] G. Mufti,et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. , 2005, Gastroenterology.
[6] K. Venkatasubbarao,et al. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. , 2005, Cancer research.
[7] M. Stratton,et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.
[8] M. Tsuneyoshi,et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. , 2003, Cancer letters.
[9] M. Vogelbaum,et al. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. , 2005, Cancer research.
[10] B. Wiedenmann,et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. , 2003, Gastroenterology.
[11] Lin Zhu,et al. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro , 2006, Cancer science.